Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: A preliminary retrospective analysis with pathologic correlation in all patients

Clinical Imaging

Volumn 37, Issue 3, 2013, Pages 451-457

  Hatzoglou, Vaios ^a   Ulaner, Gary A ^a   Zhang, Zhigang ^a   Beal, Kathryn ^a   Holodny, Andrei I ^a   Young, Robert J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Differentiating radiation injury and tumor; MRI perfusion versus FDG PET CT; PSR; RCBVmax; RPH; SUVratio

Indexed keywords

PSR; RADIATION INJURY; RCBVMAX; RPH; SUVRATIO;

BRAIN; DIAGNOSIS; FLUORINE; MAGNETIC RESONANCE; MAGNETIC SUSCEPTIBILITY; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; TUMORS;

COMPUTERIZED TOMOGRAPHY;

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN BLOOD VOLUME; BRAIN PERFUSION; BRAIN TUMOR; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION INJURY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUSCEPTIBILITY WEIGHTED IMAGING;

BRAIN INJURIES; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIATION INJURIES; RADIOPHARMACEUTICALS; RADIOTHERAPY; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84876717280     PISSN: 08997071     EISSN: 18734499     Source Type: Journal    
DOI: 10.1016/j.clinimag.2012.08.008     Document Type: Article

References (39)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005, 352:987-996.
2. Mintz A, Perry J, Spithoff K, et al. Management of single brain metastasis: a practice guideline. Curr Oncol 2007, 14:131-143.
3. Valk PE, Dillon WP Radiation injury of the brain. AJNR Am J Neuroradiol 1991, 12:45-62.
4. de Wit MC, de Bruin HG, Eijkenboom W, et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004, 63:535-537.
5. Brem S The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 1976, 23:440-453.
6. Gigtenbeek JM, Wesseling P, Maass C, et al. Three-dimensional reconstruction of tumor microvasculature: simultaneous visualization of multiple components in paraffin embedded tissue. Angiogenesis 2005, 8:297-305. [Epub 2005 Nov 19].
7. Remler MP, Marcussen WH, Tiller-Borsich J The late effects of radiation on the blood brain barrier. Int J Radiat Oncol Biol Phys 1986, 12:1965-1969.
8. Dooms JC, Hecht S, Brant-Zawadzki M, et al. Brain radiation lesions: MR imaging. Radiology 1986, 158:149-155.
9. Nishimura R, Takahashi T, Morishita S, et al. MR Gd-DTPA enhancement of radiation injury. Radiat Med 1992, 10:101-108.
10. Long DM Capillary ultrastructure in human metastatic brain tumors. J Neurosurg 1979, 51:53-58.
11. Kamiryo T, Lopes MB, Kassell NF, et al. Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 2001, 49:409-415.
12. Barajas RF, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009, 253:486-496.
13. Barajas RF, Chang JS, Sneed PK, et al. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2009, 30:367-372.
14. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30:552-558.
15. Petronas NJ, DiChiro G, Brooks RA, et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 1982, 144:885-889.
16. Ericson K, Kihlstrom L, Mogard J, et al. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irriadiated brain metastases. Stereotact Funct Neurosurg 1996, 66(Suppl. 1):214-224.
17. Chao S, Suh J, Raja S, et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001, 96:191-197.
18. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993, 186:37-44.
19. Kahn D, Follet KA, Bushnell Dl, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR Am J Roentgenol 1994, 163:1459-1465.
20. Ricci PE, Karis JP, Heiserman, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 1998, 19:407-413.
21. Brandsma D, Stalpers T, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant glioma. Lancet Oncol 2008, 9:453-461.
22. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnsotic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. AJNR Am J Neuroradiol 2010, 31:40-48.
23. Wetzel SG, Cha S, Johnson G, et al. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 2002, 224:797-803.
24. Young R, Babb J, Law M, et al. Comparison of region-of-interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas. J Magn Reson Imaging 2007, 26:1053-1063.
25. Cha S, Knopp EA, Johnson G, et al. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002, 223:11-29.
26. Graves E, Nelson S, Vigneron D, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001, 22:613-624.
27. Schlemmer H, Bachert P, Herfarth K, et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiosurgery. AJNR Am J Neuroradiol 2001, 22:1316-1324.
28. Sundgren PC MR spectroscopy in radiation injury. AJNR Am J Neuroradiol 2009, 30:1469-1476.
29. Sundgren PC, Fan X, Weybreight P, et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast enhancing lesions. Magn Reson Imaging 2006, 24:1131-1142.
30. Institute of Medicine Initial national priorities for comparative effectiveness research 2009, National Academies Press, Washington, DC.
31. 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008, 29:1176-1182.
32. 11C-methionine in the determination of malignancy of gliomas. J Neurol Sci 2006, 246:85-94.
33. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001, 96:1877-1880.
34. 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010, 112:758-765.
35. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994, 191:41-51.
36. Lupo JM, Cha S, Chang SM, et al. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol 2005, 26:1446-1454.
37. Cha S, Lu S, Johnson G, et al. Dynamic susceptibility contrast MR imaging: correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 2000, 11:114-119.
38. Cha S, Lupo JM, Chen MH, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007, 28:1078-1084.
39. Mangla R, Kholar B, Zhu T, et al. Percentage signal intensity recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain. AJNR Am J Neuroradiol 2011, 32:1004-1010.